Plasma p-tau217 has rapidly pushed to the forefront of Alzheimer’s biomarkers, proving as accurate at predicting plaques as amyloid PET. However, it is less clear how well this blood marker stacks up ...

Finding genetic variants associated with Alzheimer’s disease has been easier than figuring out exactly how they heighten risk. In the September 3 Nature, scientists led by Jubao Duan at the University ...

THY-Tau22 mice are a model for tau aggregation, a pathological hallmark of Alzheimer's disease as well as numerous tauopathies. With age these mice develop a variety of tau-related neuropathological ...

As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.

The slight slowing of cognitive decline achieved by Leqembi and perhaps by Aduhelm has revived debate around how much change is needed to be “clinically meaningful.” Two recent papers—one a report ...

The virus–Alzheimer’s tug of war continues. New data across several studies weaken the proposed, and much-debated, association; its proponents are holding fast. Short-term anti-herpes drug use ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

Many people on aducanumab (trade name Aduhelm) develop the amyloid-related imaging abnormalities (ARIA) that mark fluid retention and microhemorrhages in the brain. In the November 22 JAMA Neurology, ...

Just as the clamor about Biogen’s seeking FDA approval for aducanumab with one positive Phase 3 trial started to die down, a Chinese company garnered a regulatory thumbs-up for its drug, also with one ...